SNM Practice Guideline for Lung Scintigraphy 4.0*

J. Anthony Parker1, R. Edward Coleman2, Erin Grady3, Henry D. Royal4, Barry A. Siegel4, Michael G. Stabin5, H. Dirk Sostman6, and Andrew J.W. Hilson7

1Beth Israel Deaconess Medical Center, Boston, Massachusetts; 2Duke University Medical Center, Durham, North Carolina; 3Loyola University Medical Center, Maywood, Illinois; 4Mallinckrodt Institute of Radiology, St. Louis, Missouri; 5Vanderbilt University, Nashville, Tennessee; 6New York Hospital–Cornell Medical Center, New York, New York; and 7Royal Free Hospital, London, England

PREAMBLE

The Society of Nuclear Medicine (SNM) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. Its 16,000 members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine. In addition to publishing journals, newsletters, and books, the SNM also sponsors international meetings and workshops designed to increase the competencies of nuclear medicine practitioners and to promote new advances in the science of nuclear medicine.

The SNM will periodically define new practice guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients throughout the United States. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice guideline, representing a policy statement by the SNM, has undergone a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Committee on Guidelines and SNM Board of Directors. The SNM recognizes that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by those entities not providing these services is not authorized.

These guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNM cautions against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, there is no implication that an approach differing from the guidelines, standing alone, was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines.

The practice of medicine involves not only the science, but also the art, of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.

I. INTRODUCTION

This guideline describes the technique of performing and interpreting ventilation and perfusion scintigraphy.

II. GOALS

The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of ventilation and perfusion lung scintigraphy.
III. DEFINITIONS

Lung scintigraphy is a diagnostic imaging procedure that uses ventilation scintigraphy, perfusion scintigraphy, or both to evaluate cardiovascular and pulmonary disorders. Aerosol ventilation scintigraphy is a diagnostic imaging test that records the bronchopulmonary distribution of an inhaled radioactive aerosol within the lungs. Gas ventilation scintigraphy is a diagnostic imaging test that records the pulmonary distribution of a radioactive gas during breathing. Pulmonary perfusion scintigraphy is a diagnostic imaging test that records the distribution of pulmonary arterial blood flow. Radiographic pulmonary evaluation is a chest radiograph or CT scan used to evaluate the pulmonary parenchyma.

IV. COMMON CLINICAL INDICATIONS

Indications for lung scintigraphy include, but are not limited to, the following:

A. Most common clinical indication

The most common clinical indication for lung scintigraphy is to determine the likelihood of pulmonary embolism.

B. Less common clinical indications

1. Document the degree of resolution of pulmonary embolism.
2. Quantify differential pulmonary function before pulmonary surgery for lung cancer (1–3).
3. Evaluate lung transplants (4,5).
4. Evaluate congenital heart or lung disease such as cardiac shunts, pulmonary arterial stenoses, and arteriovenous fistulae and their treatment (6).
5. Confirm the presence of bronchopleural fistula (7,8).
6. Evaluate chronic pulmonary parenchymal disorders such as cystic fibrosis (9,10).
7. Evaluate the cause of pulmonary hypertension (11).

V. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

Refer to the SNM Guideline for General Imaging.

VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION

A. Nuclear medicine study request

1. In women of childbearing age, pregnancy and lactation status should be noted and the procedure performed in a manner to minimize radiation exposure.
2. The referring physician’s estimate of the prior probability of pulmonary embolism may be helpful. Use of validated tools such as the Wells (12) score is preferred.
3. Results of D-dimer test, if obtained, should be noted.
4. History of prior deep venous thrombosis or pulmonary embolism should be elicited.
5. Prior lung scintigraphy should be reviewed. Defects from prior pulmonary emboli do not always resolve completely.
6. Pertinent chest radiographic findings include, but are not limited to, consolidation, atelectasis, effusions, masses, cardiomegaly, and decreased pulmonary vasculature. The chest radiograph may be normal in patients with pulmonary embolism.
7. Treatment with anticoagulant or thrombolytic therapy should be noted.
8. Results of tests for deep venous thrombosis, for example, compression ultrasonography, should be noted.

B. Patient preparation and precautions

1. A standard chest radiograph in both posterior–anterior and lateral projections is preferred. A portable anterior–posterior chest radiograph is acceptable only if the patient cannot tolerate a routine chest radiographic examination. In patients who have no changes in signs or symptoms, a chest radiograph within a few days may be adequate.
2. A CT scan can substitute for the chest radiography.

C. Radiopharmaceuticals

$^{99m}$Tc has a half-life of 6 h, a photopeak of 140 keV, and isomeric transition decay. $^{133}$Xe has a half-life of 5.2 d, a photopeak of 81 keV, and β-decay. $^{81m}$Kr has a half-life of 13 s, a photopeak of 190 keV, and isomeric transition decay.

1. Aerosols

$^{99m}$Tc-diethylenetriaminepentaacetic acid (DTPA) is the most commonly used radiopharmaceutical. $^{99m}$Tc sulfur colloid is another option and has a slower clearance from the lungs. The usual dispensed activity of $^{99m}$Tc-DTPA or sulfur colloid is 900–1,300 MBq (25–35 mCi) in the nebulizer, from which the patient receives approximately 20–40 MBq (0.5–1.0 mCi) to the lungs. $^{99m}$Tc-labeled ultrafine carbon suspension has a more uniform distribution in the lungs than $^{99m}$Tc DTPA aerosol but is currently not available in the United States. Aerosol imaging is usually performed before perfusion imaging because it is more difficult to deliver a larger dose of the $^{99m}$Tc aerosol than it is to deliver a larger dose of $^{99m}$Tc-macroaggregated albumin (MAA). Because both agents are labeled with $^{99m}$Tc, it is extremely important that the counting rate of the second study is at least 3 to 4 times the counting rate of the first study.
2. **81mKr**

81mKr is obtained from an 81Rb/81mKr generator but is currently not available in the United States. 81mKr is administered by continuous inhalation of approximately 40–400 MBq (1–10 mCi).

3. **133Xe**

The usual administered activity of 133Xe is 200–750 MBq (5–20 mCi). The usual dose for children is 10–12 MBq/kg (0.3 mCi/kg), with a minimum of 100–120 MBq (3 mCi). The imaging room should provide appropriate exhaust for radioactive gas. Regulations for safe handling of radioactive gas should be followed.

4. **Perfusion**

Before intravenous administration of the pulmonary perfusion radiopharmaceutical, the patient should be instructed to cough and to take several deep breaths. The patient should be supine during injection or, in the case of a patient with orthopnea, as close to supine as possible.

The radiopharmaceutical used for perfusion imaging is 99mTc-MAA. The biologic half-life of the MAA in the lungs varies (usually 1.5–3 h).

The usual adult administered activity is 40–150 MBq (1–4 mCi). The usual pediatric administered activity is 1.11 MBq/kg (0.03 mCi/kg), with a minimum of 14.8 MBq/kg (0.4 mCi) if no 99mTc ventilation study is performed or 2.59 MBq/kg (0.07 mCi/kg) if a 99mTc ventilation study is performed (12).

The number of particles should be in the range of 200,000–700,000. For children, the number of particles should be a function of age (14).

Freshly prepared 99mTc-MAA with reduced numbers of particles should be considered for patients with pulmonary hypertension or right-to-left shunting and for infants and children. In adults, the number may be reduced to 100,000–200,000 particles without altering the quality of the images for detection of perfusion defects. Inhomogeneous distribution of activity may result from a reduction of the number of particles to below 100,000 in adults.

Labeled MAA particles will settle in the vial with time. Vials should be agitated before a dose is withdrawn, and the syringe should be inverted before injection.

### D. Protocol/image acquisition

1. **Sequence of imaging**

   A chest radiograph should be obtained and reviewed before lung scintigraphy. Ventilation scintigraphy using 133Xe is usually performed before perfusion scintigraphy. Alternately, perfusion scintigraphy can be performed first and ventilation scintigraphy omitted if not needed.

   The disadvantages of performing perfusion imaging before ventilation imaging with 133Xe are that the perfusion image contributes background activity to the ventilation image, and a decision to perform or not to perform the ventilation study must be made in a timely manner. The advantages of performing perfusion imaging before ventilation imaging with 133Xe are that if the perfusion study is normal or matches the chest radiographic findings, the ventilation study can be omitted, and for single-projection ventilation studies the projection that best shows the defect can be obtained.

   Because of the higher energy of the γ-emissions and the short half-life of 81mKr, images obtained with this gas can be alternated with those obtained with 99mTc-MAA. When 99mTc-labeled aerosol imaging is performed before 99mTc-MAA perfusion imaging, smaller amounts (20–40 MBq [0.5–1.0 mCi]) of 99mTc-labeled aerosol should be administered to the lungs.

2. **Processing**

   There are no processing steps.

3. **Aerosol ventilation imaging**

   The aerosol is administered through a mouthpiece with the nose occluded while the patient is engaging in tidal breathing.

   An advantage of aerosol imaging is that images can be obtained in multiple projections or with SPECT to match those obtained for perfusion imaging. It is preferable for the patient to be upright while inhaling the aerosol, but the patient can be supine if necessary. Aerosol ventilation imaging can be performed at the bedside. A disadvantage of aerosol imaging is that aerosol deposition is altered by turbulent flow, and central deposition can result in a suboptimal study.

   SPECT can be used to obtain a 3-dimensional evaluation of ventilation and is recommended by some investigators.

4. **133Xe ventilation imaging**

   An advantage of 133Xe ventilation is that single-breath, wash-in or equilibrium, and washout images can be obtained, thus providing a more complete characterization of ventilation and a more sensitive test for obstructive airway disease. Physiologic information about ventilation can best be obtained from 133Xe imaging.

   The imaging room should provide appropriate exhaust for radioactive gas. Regulations for safe handling of radioactive gas should be followed. The patient is positioned supine in front of the scintillation camera. If necessary, the patient can be positioned supine.

   The projection that best shows the defects on perfusion scintigraphy is used for the ventilation scintigraphy if performed after perfusion scintigraphy. Otherwise, the posterior projection is generally used. When possible, posterior oblique

---

LUNG SCINTIGRAPHY • Parker et al. 59
images should be obtained during the washout phase (and during the wash-in phase if continuous imaging is performed during this phase).

If ventilation scintigraphy is performed after perfusion scintigraphy, a $^{99m}$Tc background image should be obtained using the $^{133}$Xe window. A facemask or mouthpiece (with nose clip) should be connected via a bacterial filter to the xenon delivery system. Single-breath, equilibrium, and washout images are obtained. Equilibrium is obtained by having the patient breathe in a closed xenon delivery system for 3–4 min as tolerated.

5. $^{81m}$Kr imaging

The advantage of $^{81m}$Kr is that images can be obtained in all views without interference from prior perfusion imaging.

A disadvantage of $^{81m}$Kr is that the short half-life of the parent radionuclide, $^{81}$Rb (4.57 h), decreases availability and increases the cost of the generator.

Alternating $^{99m}$Tc-MAA and $^{81m}$Kr imaging allows ventilation and perfusion images to be obtained without patient repositioning between paired $^{99m}$Tc-MAA and $^{81m}$Kr views. The patient breathes continuously from the $^{81}$Rb/$^{81m}$Kr generator. Because of the short half-life of $^{81m}$Kr, the distribution of radioactivity approximates regional minute ventilation rate. A collimator with low septal penetration at 190 keV should be used. SPECT can be used to obtain a 3-dimensional evaluation of ventilation.

6. Perfusion imaging

After the patient has been told to cough and take several deep breaths, $^{99m}$Tc-MAA is injected slowly during 3–5 respiratory cycles with the patient supine. A well-flushed indwelling line can be used if venous access is difficult. The tracer should not be administered in the distal port of a Swan–Ganz catheter or any indwelling line or port that contains a filter—for example, a chemotherapy line.

Imaging is preferably performed with the patient upright to increase chest cavity size and to minimize diaphragmatic motion. If necessary, images can be obtained with the patient in the supine or decubitus position. Planar images should be obtained in multiple projections including anterior, posterior, both posterior oblique, both anterior oblique, and both lateral projections. Either the anterior oblique or the lateral projections can be omitted. It may be possible to obtain only limited views in some patients.

SPECT can be used to obtain a 3-dimensional evaluation of the perfusion and is recommended by some investigators. Imaging of high-blood-flow systemic organs can be used to detect right-to-left shunting. Images of the brain may be obtained to distinguish right-to-left shunting from systemic distribution of radiopharmaceutical components too small to be trapped by capillaries.

7. SPECT/low-dose CT (15,16)

Lung scintigraphy for pulmonary embolism may be performed using SPECT/low-dose CT. The low-dose CT portion of the study provides information for attenuation and, compared with a chest radiograph, also provides improved anatomic information.

Ventilation imaging is practical using an agent that has a stable distribution, $^{99m}$Tc carbon microparticles, $^{81m}$Kr, or $^{99m}$Tc aerosols. The CT portion of the study should be performed as described in the Guideline for SPECT/CT.

E. Interpretation

1. Diagnostic criteria (Table 1)

The modified PIOPED criteria were derived from a retrospective analysis of the PIOPED database (17,18). The criteria were prospectively tested and shown to be more accurate than the original PIOPED criteria (19). In an attempt to reduce the number of nondiagnostic studies, the PIOPED II criteria were modified using fewer categories. The performance of the modified PIOPED II criteria was evaluated on the PIOPED II database (20). The modified PIOPED II and PISAPED criteria using information from chest radiograph and perfusion scans have been shown to perform equivalently to those including ventilation scintigraphy, with fewer nondiagnostic studies (21).

2. Gestalt interpretation

The experienced nuclear medicine physician may be able to provide a more accurate interpretation of the ventilation–perfusion study than is provided by the criteria alone; however, the physician’s opinion is usually informed by detailed knowledge of the various lung image interpretive criteria given in E.1 (17).

3. Further interpretive considerations (22)

Ventilation–perfusion mismatch can result from any cause of pulmonary arterial blood flow obstruction. Although there is a long differential diagnosis for ventilation–perfusion mismatch, there are few common causes: acute pulmonary embolism, old pulmonary embolism, obstruction of an artery by tumor, and radiation therapy. On perfusion scintigraphy, extrapulmonary activity (which may be seen at the edges of lung images in the thyroid or kidneys) may be the result of right-to-left shunting, free $^{99m}$Tc-pertechnetate, reduced $^{99m}$Tc compounds, or another recent nuclear medicine procedure. An image of the head can be used to differentiate free $^{99m}$Tc-pertechnetate or reduced $^{99m}$Tc compounds from a right-to-left shunting.

The stripe sign (activity at the periphery of a per-
fusion defect) lowers the likelihood that a perfusion defect is due to pulmonary embolism.

4. Interpretation of right-to-left shunt studies

The presence of a right-to-left shunt is identified by activity in systemic vascular beds. An image of the head provides the most accurate method to detect small shunts. Activity due to shunting of $^{99m}$Tc-MAA particles will correspond to brain perfusion, whereas other activity will be seen in the scalp. The fraction of right-to-left shunting can be approximated by comparing the activity in the lungs to the activity in the rest of the body.

5. Interpretation of preoperative lung scintigraphy

Each lung is generally divided into 3 equal rectangular regions of interest on anterior and posterior views: top, middle, and bottom. The activity in the 6 regions of interest is reported for perfusion or for both ventilation and perfusion. An anatomically based description of the perfusion should be provided. Alternative methods of quantification with regions that correspond more closely to pulmonary anatomy are preferred by some experts.

6. Interpretation of posttransplantation lung scintigraphy

In the immediate posttransplantation setting, perfusion imaging documents the patency of the vascu-

---

### TABLE 1

Ventilation, Perfusion, and Radiographic Interpretive Criteria for Pulmonary Embolism

<table>
<thead>
<tr>
<th>PIOPED</th>
<th>Modified PIOPED II</th>
<th>Perfusion-only modified PIOPED II</th>
<th>Perfusion-only PISAPED</th>
</tr>
</thead>
<tbody>
<tr>
<td>High LR</td>
<td>High LR</td>
<td>PE present</td>
<td>PE present</td>
</tr>
<tr>
<td>&gt;2 large mismatched (V:Q) segmental defects*</td>
<td>≥2 large mismatched (V:Q) segmental defects*</td>
<td>≥2 large mismatched (Q:CXR) segmental defects*</td>
<td>≥1 wedge-shaped Q defects</td>
</tr>
<tr>
<td>Borderline high LR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 large mismatched (V:Q) segmental defects*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate LR</td>
<td></td>
<td>Nondiagnostic</td>
<td>Nondiagnostic</td>
</tr>
<tr>
<td>2 moderate or 1 large mismatched (V:Q) defect*</td>
<td></td>
<td>All other findings</td>
<td>All other findings</td>
</tr>
<tr>
<td>Difficult to categorize as high or low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borderline low LR</td>
<td></td>
<td>Nondiagnostic</td>
<td>Nondiagnostic</td>
</tr>
<tr>
<td>1 matched (V:Q) defect, CXR-negative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low LR</td>
<td></td>
<td>Nonsegmental†</td>
<td>Nonsegmental†</td>
</tr>
<tr>
<td>Q defect substantially &lt; CXR defect</td>
<td></td>
<td>Nonsegmental†</td>
<td>Nonsegmental†</td>
</tr>
<tr>
<td>Matched (V:Q) defects, CXR-negative</td>
<td></td>
<td>Any number of small Q defects*</td>
<td>Any number of small Q defects*</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>No Q defects</td>
<td></td>
<td>Nonsegmental†</td>
<td>Nonsegmental†</td>
</tr>
<tr>
<td>Q defect &lt; CXR lesion</td>
<td></td>
<td>Q defect &lt; CXR lesion</td>
<td>Q defect &lt; CXR lesion</td>
</tr>
<tr>
<td>1–3 small segmental* defects</td>
<td></td>
<td>1–3 small segmental* defects</td>
<td>1–3 small segmental* defects</td>
</tr>
<tr>
<td>Solitary matched (V:Q:CXR) defect (≤1 segment) in mid or upper lung</td>
<td></td>
<td>Solitary matched (Q:CXR) defect (≤1 segment) in mid or upper lung</td>
<td></td>
</tr>
<tr>
<td>Stripe sign‡</td>
<td></td>
<td>Stripe sign‡</td>
<td>Stripe sign‡</td>
</tr>
<tr>
<td>Solitary large pleural effusion§</td>
<td></td>
<td>Solitary large pleural effusion§</td>
<td></td>
</tr>
<tr>
<td>≥2 matched (V:Q) defects, regionally normal CXR</td>
<td></td>
<td>≥2 matched (V:Q) defects, regionally normal CXR</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>No Q defects</td>
<td></td>
<td>Normal</td>
<td>Normal</td>
</tr>
</tbody>
</table>

*Or equivalent where large segmental defect, >75% of segment, equals 1 segmental equivalent; moderate defect, 25%–75% of segment, equals 0.5 segmental equivalent; small defect, <25%, is not counted.

†For example, prominent hilum, cardiomegaly, elevated diaphragm, linear atelectasis, or costophrenic angle effusion with no other perfusion defect in either lung and no other radiographic lesion.

‡Peripheral perfusion in a defect (best seen on tangential view).

§Pleural effusion in at least one third of pleural cavity, with no other perfusion defect in either lung.

§Perfusion defects exactly match shape of CXR.

V:Q = ventilation–perfusion; CXR = chest radiograph; PE = pulmonary embolism; LR = likelihood ratio.
lar anastomoses. In single-lung transplantation, the ratio of right-to-left lung perfusion and the change in ratio correlate with rejection. Analysis of regional changes in ventilation and perfusion may also be useful. Development of matched ventilation perfusion abnormalities consistent with obstructive lung disease often reflects rejection (bronchiolitis obliterans).

7. Sources of error

Perfusion images can show hot spots in the lung if clotting of blood occurs in the syringe during the injection or if the injection is made through an indwelling catheter that is not well flushed.

Ventilation scintigraphy is obtained at a different point in time from perfusion scintigraphy. In the intervening time, there can be changes in ventilation and perfusion. Similarly, ventilation scintigraphy may be obtained with the patient upright, and the radiopharmaceutical for perfusion scintigraphy typically is injected with the patient supine. These changes in position may also affect the comparability of the 2 scintigrams.

Injection of 99mTc-MAA through a central line can result in inadequate mixing of activity in the pulmonary artery. This inadequate distribution of activity is especially true if the activity is injected through a pulmonary artery line.

A decubitus or oblique patient position can markedly affect the distribution of ventilation and perfusion. If ventilation scintigraphy or the injection for perfusion scintigraphy is performed with the patient in the decubitus or oblique position, mismatched patterns can result. Accordingly, any nonstandard patient positioning should be recorded and considered during subsequent interpretation.

Activity in the thyroid is often used as an indicator of free 99mTc-pertechnetate in the radiopharmaceutical preparation. However, the thyroid is also a high-flow organ and may be visualized in the case of a right-to-left shunt.

8. Issues requiring further clarification

There is considerable literature on SPECT lung scintigraphy, and there is emerging literature on SPECT/low-dose CT lung scintigraphy (23). However, there is currently no information about the comparison of these methods with planar imaging in a multiinstitutional setting (24). The criteria for interpretation of SPECT and SPECT/low-dose CT need to be established. The utility of breathing maneuvers or gating in the context of SPECT and SPECT/low-dose CT needs to be established. The radiation-absorbed dose that provides adequate diagnostic information for use in low-dose CT needs to be established. Finally, the utility of adding ventilation imaging to anatomic and perfusion imaging needs further study (21,23).

F. Interventions

In patients with acute obstructive lung disease, the use of bronchodilator therapy before lung scintigraphy may decrease ventilatory defects and improve the accuracy of the study. Because perfusion defects often change as acute obstruction resolves, patients are best imaged when bronchospasm has resolved. In patients with congestive heart failure, improved specificity will be obtained if imaging can be delayed until therapy for heart failure has been instituted.

VII. DOCUMENTATION/REPORTING

A. Goals of a nuclear medicine report

Refer to the SNM Guideline for General Imaging.

B. Direct communication

Refer to the SNM Guideline for General Imaging.

C. Written communication

Refer to the SNM Guideline for General Imaging.

D. Contents of the nuclear medicine report

Refer to the SNM Guideline for General Imaging.

1. Study identification

---

TABLE 2

Radiation Dosimetry in Adults

<table>
<thead>
<tr>
<th>Radiopharmaceutical</th>
<th>Administered activity</th>
<th>Largest radiation dose</th>
<th>Effective dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MBq</td>
<td>mCi</td>
<td>Organ</td>
</tr>
<tr>
<td>99mTc-MAA†</td>
<td>40–150</td>
<td>1.1–4.1</td>
<td>Lung</td>
</tr>
<tr>
<td>99mTc-DTPA‡</td>
<td>20–40</td>
<td>0.54–1.1</td>
<td>Bladder</td>
</tr>
<tr>
<td>133Xe§</td>
<td>200–750</td>
<td>5.4–20</td>
<td>Lung</td>
</tr>
<tr>
<td>81mKr k</td>
<td>40–400</td>
<td>1.1–11</td>
<td>Lung</td>
</tr>
</tbody>
</table>

*Data are from (31).
†Data are from (30), page 224.
‡Data are from (30), page 218.
§Data are from (30), page 345, rebreathing for 5 min.
kData are from (30), page 160.
2. Clinical information

3. Procedure description

4. Description of findings

The report should include a description of the lung scintigraphy findings, diagnostic category, and an overall assessment of the likelihood of pulmonary embolism based on the scintigraphic findings. Terms referring to test outcome, for example, “likelihood ratio for pulmonary embolism,” are preferred over terms referring to posterior probability, for example, “probability of pulmonary embolism.”

5. Impression

6. Comments

The report may include an assessment of the post-test probability of pulmonary embolism based on the result of lung scintigraphy and an estimate of the prior probability of disease (25,26). Many experts believe limiting reporting to 3 categories—pulmonary embolism present, pulmonary embolism absent, and nondiagnostic (intermediate likelihood ratio)—facilitates communication. Some believe more accurate categorization provides more information to referring physicians (16). The outcome of patients with low-likelihood-ratio lung scans is good (27–29).
VIII. EQUIPMENT SPECIFICATION

A. Ventilation
A disposable nebulizer is needed for 99mTc-labeled aerosol. A xenon gas ventilation system should include capabilities for single-breath, wash-in or equilibrium, and washout phases. A xenon trap should be available for exhausted gas. An ultrafine dispersion of 99mTc-labeled carbon produced using a commercial system is not currently available in the United States.

B. Planar imaging
Refer to the SNM Guideline for General Imaging.

C. SPECT
Refer to the SNM Guideline for General Imaging.

D. SPECT/CT
Refer to the SNM Guideline for SPECT/CT.

IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
Refer also to the SNM Guideline for General Imaging.
Radiochemical purity and particle size determination of 99mTc-MAA should be performed. Reconstituted MAA should be stored in a refrigerator and used before expiration. Dose reduction in pediatric imaging is always desirable, as long as image quality is maintained (13).

X. RADIATION SAFETY IN IMAGING
Radiation dosimetry in adults, 5-yr-old children, and the fetus are presented in Tables 2–7.
Regarding the breastfeeding patient, ICRP Publication 106, Appendix D, suggests a 12-h interruption of breast feeding for subjects receiving 150 MBq (4.1 mCi) of 99mTc-MAA; it does not provide a recommendation about interruption of breastfeeding for 99mTc-DTPA aerosols (but suggests that no interruption is needed for 99mTc-DTPA intravenously administered or 99mTc-Technegas [Cyclomedica Ltd.]); the authors recommend that no interruption is needed for breastfeeding patients administered 133Xe or 81mKr.

XI. ACKNOWLEDGMENTS
The Committee on SNM Guidelines consists of the following individuals: Kevin J. Donohoe, MD (Chair) (Beth Israel Deaconess Medical Center, Boston, MA); Dominique Delbeke, MD (Vanderbilt University Medical Center, Nashville, TN); Sue Abreu, MD (Sue Abreu Consulting, Nichols Hills, OK); Twyla Bartel, DO (UAMS, Little Rock, AR); Paul E. Christian, CNMT, BS, PET (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT); S. James Cullom, PhD (Cardiovascular Imaging Technology, Kansas City, MO); Vasken Dilsizian, MD (University of Maryland Medical Center, Baltimore, MD); Kent Friedman, MD (NYU School of Medicine, New York, NY); Luis Hidalgo, MD (Northwestern University, Chicago, IL); and Mary L. Lauer, MD (Johns Hopkins School of Medicine, Baltimore, MD). The Committee thanks the following contributors: Andrew C. January, MD (Kaiser Permanente, Vancouver, WA); Jennifer K. Johnson, MD, PhD (University of Washington, Seattle, WA); and Patrick H. Kinahan, MD (University of Washington, Seattle, WA).

TABLE 6
133Xe: Dose Estimates to the Fetus

<table>
<thead>
<tr>
<th>Stage of gestation</th>
<th>mGy/MBq</th>
<th>rad/mCi</th>
<th>mGy*</th>
<th>rad*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early</td>
<td>0.00025</td>
<td>0.00092</td>
<td>0.050–0.19</td>
<td>0.0050–0.019</td>
</tr>
<tr>
<td>3 mo</td>
<td>0.000029</td>
<td>0.00011</td>
<td>0.0058–0.022</td>
<td>0.00058–0.0022</td>
</tr>
<tr>
<td>6 mo</td>
<td>0.000021</td>
<td>0.000078</td>
<td>0.0042–0.016</td>
<td>0.00042–0.0016</td>
</tr>
<tr>
<td>9 mo</td>
<td>0.000016</td>
<td>0.000059</td>
<td>0.0032–0.01</td>
<td>0.00032–0.0012</td>
</tr>
</tbody>
</table>

*Maternal administered activity, 200–750 MBq (5.4–20 mCi).
Data are from Russell et al. (32). No information about possible placental crossover of this compound was available for use in estimating fetal doses.

TABLE 7
81mKr: Dose Estimates to the Fetus

<table>
<thead>
<tr>
<th>Stage of gestation</th>
<th>mGy/MBq</th>
<th>rad/mCi</th>
<th>mGy*</th>
<th>rad*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early</td>
<td>1.8 × 10^-7</td>
<td>6.7 × 10^-7</td>
<td>7.2 × 10^-6 to 7.2 × 10^-6</td>
<td>7.2 × 10^-6 to 7.2 × 10^-6</td>
</tr>
<tr>
<td>3 mo</td>
<td>1.8 × 10^-7</td>
<td>6.7 × 10^-7</td>
<td>7.2 × 10^-6 to 7.2 × 10^-6</td>
<td>7.2 × 10^-6 to 7.2 × 10^-6</td>
</tr>
<tr>
<td>6 mo</td>
<td>2.8 × 10^-7</td>
<td>1.0 × 10^-6</td>
<td>1.1 × 10^-5 to 1.1 × 10^-5</td>
<td>1.1 × 10^-5 to 1.1 × 10^-5</td>
</tr>
<tr>
<td>9 mo</td>
<td>3.4 × 10^-7</td>
<td>1.3 × 10^-6</td>
<td>1.4 × 10^-5 to 1.4 × 10^-5</td>
<td>1.4 × 10^-5 to 1.4 × 10^-5</td>
</tr>
</tbody>
</table>

*Maternal administered activity, 40–400 MBq (1.1–11 mCi).
Dose estimates to the fetus were not provided by Russell et al. (32) but were estimated using kinetic data in ICRP 53. No information about possible placental crossover of this compound was available for use in estimating fetal doses.
York, NY); Jay A. Harolds, MD (OUHSC-Department of Radiological Science, Edmond, OK); Aaron Jessop, MD (Vanderbilt University Medical Center, Nashville, TN); J. Anthony Parker, MD, PhD (Beth Israel Deaconess Medical Center, Boston, MA); Rebecca A. Sajdak, CNMT, FSNMTS (Loyola University Medical Center, Maywood, IL); Heiko Schoder, MD (Memorial Sloan-Kettering Cancer Center, New York, NY); Barry L. Shulkan, MD, MBA (St. Jude Children’s Research Hospital, Memphis, TN); Michael G. Stabin, PhD (Vanderbilt University, Nashville, TN); Mark Tulchinsky, MD (Milton S. Hershey Medical Center, Hershey, PA); and Jerold W. Wallis, MD (Mallinckrodt Institute of Radiology, St. Louis, MO).

XII. REFERENCES


XIII. APPROVAL

This practice guideline (version 4.0) was approved by the Board of Directors of the SNM on July 19, 2011. Version 1.0 was approved on January 14, 1996; version 2.0 on February 7, 1999; and version 3.0 on February 7, 2004.